Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

S*Bio Signs $550 Million Deal with Onyx

publication date: Jan 8, 2009

S*BIO of Singapore has optioned its two leading drug candidates to Onyx Pharmaceuticals in a deal that could be worth up to $550 million. As an upfront payment, S*Bio will receive $25 million in a combination of cash and equity investment. The agreement gives Onyx the right to exercise its options for S*BIO’s JAK2 inhibitors, SB1518 and SB1578, at certain predetermined development points. Each drug will be optioned separately. At that point, Onyx will have an exclusive license for all indications for the specific drug in the US, Canada and Europe. More details...

Stock Symbols: (NSDQ: ONXX) (NYSE: NVS)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital